OBJECTIVES: To compare asymmetric dimethylarginine (ADMA) among HIV-infected and uninfected individuals and to evaluate predictors of ADMA in HIV infection. BACKGROUND: HIV-infected individuals have high rates of atherosclerosis. Endothelial dysfunction is central to atherogenesis and is one possible mechanism underlying this increased cardiovascular risk. ADMA is an endogenous inhibitor of endothelial nitric oxide synthase. Among uninfected individuals, higher ADMA levels predict cardiovascular events and mortality. The association between HIV infection, HIV-related factors, and ADMA has not been well described. METHODS: We compared ADMA in 248 HIV-infected individuals and 50 uninfected controls. We performed multivariable analysis using traditional cardiovascular and HIV-specific factors as covariates to identify factors associated with ADMA. RESULTS: HIV-infected men were older, less often Caucasian, more hypertensive, and had lower HDL than uninfected men. The median duration of HIV infection was 13 years, median CD4+ count was 592 cells/μL, 76% had an undetectable viral load, and 76% were on antiretroviral therapy. ADMA levels were modestly higher in HIV-infected individuals than controls [median (IQR): 0.46 μM (0.41-0.52) vs. 0.44 μM (0.38-0.46), p = 0.019], but the association lost statistical significance after controlling for cardiovascular risk factors (+0.028 μM, p = 0.054). Lower CD4+ count and both detectable and higher viral load were independently associated with increased ADMA. CONCLUSIONS: ADMA levels were modestly elevated in the setting of HIV infection. Notably, a greater HIV-associated inflammatory burden, as evidenced by lower CD4+ counts and higher viral loads, was associated with increased ADMA levels. Our findings suggest that HIV infection impairs endothelial function and predisposes to atherosclerosis through chronic inflammation and subsequent accumulation of ADMA.
OBJECTIVES: To compare asymmetric dimethylarginine (ADMA) among HIV-infected and uninfected individuals and to evaluate predictors of ADMA in HIV infection. BACKGROUND:HIV-infected individuals have high rates of atherosclerosis. Endothelial dysfunction is central to atherogenesis and is one possible mechanism underlying this increased cardiovascular risk. ADMA is an endogenous inhibitor of endothelial nitric oxide synthase. Among uninfected individuals, higher ADMA levels predict cardiovascular events and mortality. The association between HIV infection, HIV-related factors, and ADMA has not been well described. METHODS: We compared ADMA in 248 HIV-infected individuals and 50 uninfected controls. We performed multivariable analysis using traditional cardiovascular and HIV-specific factors as covariates to identify factors associated with ADMA. RESULTS:HIV-infectedmen were older, less often Caucasian, more hypertensive, and had lower HDL than uninfected men. The median duration of HIV infection was 13 years, median CD4+ count was 592 cells/μL, 76% had an undetectable viral load, and 76% were on antiretroviral therapy. ADMA levels were modestly higher in HIV-infected individuals than controls [median (IQR): 0.46 μM (0.41-0.52) vs. 0.44 μM (0.38-0.46), p = 0.019], but the association lost statistical significance after controlling for cardiovascular risk factors (+0.028 μM, p = 0.054). Lower CD4+ count and both detectable and higher viral load were independently associated with increased ADMA. CONCLUSIONS:ADMA levels were modestly elevated in the setting of HIV infection. Notably, a greater HIV-associated inflammatory burden, as evidenced by lower CD4+ counts and higher viral loads, was associated with increased ADMA levels. Our findings suggest that HIV infection impairs endothelial function and predisposes to atherosclerosis through chronic inflammation and subsequent accumulation of ADMA.
Authors: Virginia A Triant; Susan Regan; Hang Lee; Paul E Sax; James B Meigs; Steven K Grinspoon Journal: J Acquir Immune Defic Syndr Date: 2010-12-15 Impact factor: 3.731
Authors: R H Böger; S M Bode-Böger; A Szuba; P S Tsao; J R Chan; O Tangphao; T F Blaschke; J P Cooke Journal: Circulation Date: 1998-11-03 Impact factor: 29.690
Authors: Rainer H Böger; Lisa M Sullivan; Edzard Schwedhelm; Thomas J Wang; Renke Maas; Emelia J Benjamin; Friedrich Schulze; Vanessa Xanthakis; Ralf A Benndorf; Ramachandran S Vasan Journal: Circulation Date: 2009-03-16 Impact factor: 29.690
Authors: Francesca J Torriani; Lauren Komarow; Robert A Parker; Bruno R Cotter; Judith S Currier; Michael P Dubé; Carl J Fichtenbaum; Mariana Gerschenson; Carol K C Mitchell; Robert L Murphy; Kathleen Squires; James H Stein Journal: J Am Coll Cardiol Date: 2008-08-12 Impact factor: 24.094
Authors: Jason V Baker; Jacqueline Neuhaus; Daniel Duprez; Matthew Freiberg; Jose I Bernardino; Andrew D Badley; Daniel E Nixon; Jens D Lundgren; Russell P Tracy; James D Neaton Journal: J Acquir Immune Defic Syndr Date: 2012-06-01 Impact factor: 3.731
Authors: Nicole M Willemsen; Eleanor M Hitchen; Tracey J Bodetti; Ann Apolloni; David Warrilow; Sabine C Piller; David Harrich Journal: Retrovirology Date: 2006-12-15 Impact factor: 4.602
Authors: Matthew J Feinstein; Brian Poole; Pedro Engel Gonzalez; Anna E Pawlowski; Daniel Schneider; Tim S Provias; Frank J Palella; Chad J Achenbach; Donald M Lloyd-Jones Journal: J Nucl Cardiol Date: 2016-10-13 Impact factor: 5.952
Authors: Marius Trøseid; Ingjerd W Manner; Karin K Pedersen; Judith M Haissman; Dag Kvale; Susanne D Nielsen Journal: AIDS Res Hum Retroviruses Date: 2014-03-25 Impact factor: 2.205
Authors: Rushi V Parikh; Rebecca Scherzer; Elaine M Nitta; Anna Leone; Sophia Hur; Vanita Mistry; John S Macgregor; Jeffrey N Martin; Steven G Deeks; Peter Ganz; Priscilla Y Hsue Journal: AIDS Date: 2014-02-20 Impact factor: 4.177
Authors: Meghan E Fitzpatrick; Mehdi Nouraie; Matthew R Gingo; Danielle Camp; Cathy J Kessinger; James B Sincebaugh; Andrew Clarke; John W Ries; Eric C Kleerup; Lawrence Kingsley; Alison Morris Journal: AIDS Date: 2016-06-01 Impact factor: 4.177
Authors: Sahera Dirajlal-Fargo; Vanessa El Kamari; Abdus Sattar; Khurshid Alam; Nicholas Funderburg; Danielle Labbato; Lisa Pirro; Chris T Longenecker; Wai Hong Wilson; Grace A McComsey Journal: Atherosclerosis Date: 2017-09-28 Impact factor: 5.162
Authors: Matthew R Gingo; Yingze Zhang; Kidane B Ghebrehawariat; Jong-Hyeon Jeong; Yanxia Chu; Quanwei Yang; Lorrie Lucht; David B Hanna; Jason M Lazar; Mark T Gladwin; Alison Morris Journal: PLoS One Date: 2015-03-26 Impact factor: 3.240
Authors: Rushi V Parikh; Yifei Ma; Rebecca Scherzer; Amanda S Heringer; John S Macgregor; Jeffrey N Martin; Steven G Deeks; Peter Ganz; Priscilla Y Hsue Journal: PLoS One Date: 2016-01-11 Impact factor: 3.240